SEC Form 4 · accession 0001093557-18-000244
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Doubleday
Officer — EVP, Chief Commercial Officer
Period of report
Nov 23, 2018
Accepted (ET)
Nov 27, 2018 · 6:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Nov 23, 2018 | S | 500 | $119.738 | D | 16,858 | I | by Trust |
| Common StockF1,F4,F3 | Nov 23, 2018 | S | 1,236 | $122.0024 | D | 15,622 | I | by Trust |
| Common Stock | holding | — | — | — | 66,804 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- F2This transaction was executed in multiple trades at prices ranging from $119.64 to $120.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F3Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.
- F4This transaction was executed in multiple trades at prices ranging from $122.00 to $122.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.